Sarepta Therapeutics (SRPT) volatility pulls back on sharp rally on FDA approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Sarepta Therapeutics (SRPT) Shares on Watch Amid Chatter of Secondary Stock Offering
September 20, 2016 3:09 PM EDTSarepta Therapeutics (Nasdaq: SRPT) shares are on watch amid speculation of an impending secondary stock offering. No official announcement has been made yet.
... MoreSarepta (SRPT) Wins Key PTO Decision on Composition of Matter Patents - Oppenheimer
September 20, 2016 1:18 PM EDTOppenheimer analyst Michelle Gilson notes US Patent and Trademark Office ruled in favor of Sarepta (NASDAQ: SRPT) for Patents 7,960,541 and 7,807,816 in its patent interference proceeding (interference number 106,008).
Gilson notes these cover composition of matter for eteplirsen, giving the Sarepta freedom to operate... More
